🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Waldenstrom Macroglobulinemia

Observational Study Evaluating the Efficacy and Safety of Zanubrutinib in Participants With Waldenström Macroglobulinemia NCT05640102n/a8 sites📍 Huntsville📍 Mobile📍 Duarte BeiGene · Tests: Zanubrutinib Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer NCT01137643n/a1 site📍 Chapel Hill UNC Lineberger Comprehensive Cancer Center · Tests: biologic sample preservation procedure, cytology specimen collection procedure Cosibelimab for CSCC in Patients With Kidney Transplant or Hematologic Malignancy NCT07426484Phase 42 sites📍 Boston📍 Boston Dana-Farber Cancer Institute · Tests: Cosibelimab, Prednisone, Sirolimus, Everolimus Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome NCT02269592n/a7 sites📍 Boston📍 Brighton📍 Methuen Dana-Farber Cancer Institute Combating Cancer-Related Fatigue: A Personalized Supportive Care Program NCT06860880NA1 site📍 Chapel Hill UNC Lineberger Comprehensive Cancer Center · Tests: Exercise, Diet Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Lymphoplasmacytic Lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM), and Splenic Marginal Zone Lymphoma (SMZL) NCT00923507n/a1 site📍 Bethesda National Heart, Lung, and Blood Institute (NHLBI) Efficacy of Venetoclax in Combination With Rituximab in Waldenström's Macroglobulinemia NCT05099471Phase 214 sites📍 Bielefeld📍 Chemnitz📍 Kempten Christian Buske · Tests: Venetoclax; Rituximab, DRC A Study of ARC-02 in B-cell NHL NCT07691606Phase 129 sites📍 Los Angeles📍 Louisville📍 New York Taiho Oncology, Inc. · Tests: ARC-02, Rituximab A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies NCT04830137Phase 116 sites📍 Duarte📍 Orange📍 San Francisco Nurix Therapeutics, Inc. · Tests: NX-2127 Rituximab and Ibrutinib (RI) Versus Dexamethasone, Rituximab and Cyclophosphamide (DRC) as Initial Therapy for Waldenström's Macroglobulinaemia NCT04061512Phase 2, Phase 325 sites📍 Bath📍 Bournemouth📍 Canterbury University College, London · Tests: Dexamethasone, cyclophosphamide, rituximab, Rituximab, ibrutinib Registry Platform Hematologic Malignancies (RUBIN) - Extension of Tumor Registry Lymphatic Neoplasms NCT06043011n/a1 site📍 Freiburg im Breisgau iOMEDICO AG · Tests: Routine care as per site standard. Dose Escalation and Dose Expansion Study of MDX2003 in Patients With Different Types of Lymphoma NCT07249905Phase 1, Phase 26 sites📍 Richmond📍 Nedlands📍 Haifa ModeX Therapeutics, An OPKO Health Company · Tests: MDX2003 Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader NCT05294731Phase 1, Phase 229 sites📍 Bengbu📍 Hefei📍 Beijing BeOne Medicines · Tests: Tacabrutideg Clinical Study of the Hyperviscosity Syndrome in Waldenström Macroglobulinemia NCT04898647NA1 site📍 Amiens Centre Hospitalier Universitaire, Amiens · Tests: fundoscopic picture, blood sample, bone marrow sample Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma NCT04840602Phase 2150 sites📍 Tucson📍 Tucson📍 Irvine National Cancer Institute (NCI) · Tests: Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Ibrutinib Prognostic Value of Circulating Tumoral DNA After the First 6 Months of Treatment in Patients With Waldenström Macroglobulinemia NCT04893564NA1 site📍 Amiens Centre Hospitalier Universitaire, Amiens · Tests: bone marrow sample, blood sample A Study of Rocbrutinib in Combination With Lacutoclax in Patients With B-Cell Malignancies NCT07609862Phase 1, Phase 21 site📍 Tianjin Guangzhou Lupeng Pharmaceutical Company LTD. · Tests: Lacutoclax+Rocbrutinib Registry of Older Patients With Cancer NCT01137825n/a7 sites📍 Boone📍 Chapel Hill📍 Greenville UNC Lineberger Comprehensive Cancer Center This Study Aims to Clarify the Prevalence and Characteristics of Neuropathy, Along With Associated Paraclinical Findings in Patients With Waldenström's Macroglobulinemia (WM) in a Cohort of WM Patients to Optimize the Diagnostic Process NCT07160270n/a1 site📍 København Ø Copenhagen University Hospital, Rigshospitalet Epcoritamab in Previously Treated WM NCT06510491Phase 23 sites📍 Boston📍 Boston📍 Chapel Hill Gottfried von Keudell, MD PhD · Tests: Epcoritamab Q702 for the Treatment of Patients With Hematologic Malignancies NCT06712810Phase 12 sites📍 Scottsdale📍 Rochester Mayo Clinic · Tests: Axl/Mer/CSF1R Inhibitor Q702, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography Implanted Loop Recorders for Detection and Management of Arrhythmia With Bruton Tyrosine Kinase Inhibitors NCT05643235NA1 site📍 New Hyde Park Northwell Health · Tests: Medtronic LINQ-2 Insertable Cardiac Monitor (ILR) Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies. NCT04775745Phase 14 sites📍 Durham📍 Cincinnati📍 Columbus Newave Pharmaceutical Inc · Tests: LP-168, LP-168 A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies NCT05780034Phase 19 sites📍 Denver📍 Sarasota📍 Chapel Hill Accutar Biotechnology Inc · Tests: AC676 AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas NCT06340737Phase 11 site📍 Palo Alto Stanford University · Tests: CD22CART Infusion Spanish Registry of Patients With IgM Monoclonal Gammopathies NCT05093153n/a51 sites📍 Mérida📍 Palma📍 Palma de Mallorca Fundación Española de Hematología y Hemoterapía AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma NCT05602363Phase 113 sites📍 Orange📍 Miami Beach📍 Tampa Carna Biosciences, Inc. · Tests: Docirbrutinib A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies NCT05006716Phase 1, Phase 2114 sites📍 Birmingham📍 Phoenix📍 Scottsdale BeOne Medicines · Tests: Tacabrutideg Study of SGR-1505 in Mature B-Cell Neoplasms NCT05544019Phase 136 sites📍 Gilbert📍 Newark📍 Pompano Beach Schrödinger, Inc. · Tests: SGR-1505 Zanubrutinib, Bendamustine, Rituximab Prev. Untreated WM NCT06561347Phase 25 sites📍 Denver📍 Boston📍 Boston Massachusetts General Hospital · Tests: Zanubrutinib, Bendamustine, Rituximab
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy